These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 18589304)

  • 61. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice.
    Carlo-Stella C; Guidetti A; Di Nicola M; Longoni P; Cleris L; Lavazza C; Milanesi M; Milani R; Carrabba M; Farina L; Formelli F; Gianni AM; Corradini P
    Exp Hematol; 2006 Jun; 34(6):721-7. PubMed ID: 16728276
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Alemtuzumab (Millennium/ILEX).
    Dumont FJ
    Curr Opin Investig Drugs; 2001 Jan; 2(1):139-60. PubMed ID: 11527007
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation.
    Weissenbacher A; Boesmueller C; Brandacher G; Oellinger R; Pratschke J; Schneeberger S
    Immunotherapy; 2010 Nov; 2(6):783-90. PubMed ID: 21091110
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN.
    Visser GW; Klok RP; Gebbinck JW; ter Linden T; van Dongen GA; Molthoff CF
    J Nucl Med; 2001 Mar; 42(3):509-19. PubMed ID: 11337531
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Measuring humanized antibodies in plasma of patients treated with antibody-based therapy using bead-based flow cytometry: the story of alemtuzumab.
    Chan HE; Jilani I; Chang R; Albitar M
    Methods Mol Biol; 2007; 378():159-65. PubMed ID: 18605084
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.
    Santos DD; Hatjiharissi E; Tournilhac O; Chemaly MZ; Leleu X; Xu L; Patterson C; Branagan AR; Manning RJ; Ho AW; Hunter ZR; Dimmock EA; Kutok JL; Churchill WH; Castells MC; Tai YT; Anderson KC; Treon SP
    Clin Lymphoma Myeloma; 2006 May; 6(6):478-83. PubMed ID: 16796779
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies.
    Guyre CA; Gomes D; Smith KA; Kaplan JM; Perricone MA
    J Immunol Methods; 2008 Apr; 333(1-2):51-60. PubMed ID: 18314132
    [TBL] [Abstract][Full Text] [Related]  

  • 69. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.
    Demko S; Summers J; Keegan P; Pazdur R
    Oncologist; 2008 Feb; 13(2):167-74. PubMed ID: 18305062
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
    Robak T
    Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
    Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
    J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab.
    Sasaki M; Sugimoto K; Mori T; Karasawa K; Oshimi K
    Acta Haematol; 2008; 119(1):48-53. PubMed ID: 18259114
    [TBL] [Abstract][Full Text] [Related]  

  • 73. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.
    Nagengast WB; de Vries EG; Hospers GA; Mulder NH; de Jong JR; Hollema H; Brouwers AH; van Dongen GA; Perk LR; Lub-de Hooge MN
    J Nucl Med; 2007 Aug; 48(8):1313-9. PubMed ID: 17631557
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
    Rogers BE; Roberson PL; Shen S; Khazaeli MB; Carpenter M; Yokoyama S; Brechbiel MW; LoBuglio AF; Buchsbaum DJ
    Cancer Biother Radiopharm; 2005 Oct; 20(5):502-13. PubMed ID: 16248766
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Monoclonal antibody therapy of leukaemias and lymphomas.
    Jacobs SA; Foon KA
    Expert Opin Biol Ther; 2005 Sep; 5(9):1225-43. PubMed ID: 16120052
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immune status following alemtuzumab treatment in human CD52 transgenic mice.
    Turner MJ; Lamorte MJ; Chretien N; Havari E; Roberts BL; Kaplan JM; Siders WM
    J Neuroimmunol; 2013 Aug; 261(1-2):29-36. PubMed ID: 23759318
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Residual cancer lymphocytes in patients with chronic lymphocytic leukemia after therapy show increased expression of surface antigen CD52 detected using quantitative fluorescence cytometry.
    Pevna M; Doubek M; Coupek P; Stehlikova O; Klabusay M
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):411-8. PubMed ID: 25066039
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Rhenium-186-mercaptoacetyltriglycine-labeled monoclonal antibody for radioimmunotherapy: in vitro assessment, in vivo kinetics and dosimetry in tumor-bearing nude mice.
    Kinuya S; Yokoyama K; Tega H; Hiramatsu T; Konishi S; Yamamoto W; Shuke N; Aburano T; Watanabe N; Takayama T; Michigishi T; Tonami N
    Jpn J Cancer Res; 1998 Aug; 89(8):870-8. PubMed ID: 9765625
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia.
    Osterborg A; Mellstedt H; Keating M
    Med Oncol; 2002; 19 Suppl():S21-6. PubMed ID: 12180488
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Monoclonal antibody therapy for B-cell malignancies.
    Cheson BD
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S2-14. PubMed ID: 16720198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.